Total revenue was $200.5 million, or $201.3 million on a non-GAAP constant currency basis, for the full year 2024, representing 3.9% and 3.9% increases, respectively, over the full year 2023 Expanded ...

“I am encouraged by the resilience of our portfolio amidst a challenging macroeconomic backdrop, exemplified by double-digit revenue growth in Cytek cell sorters and our service business, and strength ...

Cytek Biosciences, Inc. announced that it will report its financial results for the fourth quarter and full year 2024 on February 27, 2025, after market close. A conference call to discuss these ...

Cytek Biosciences, Inc. ((CTKB)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call of Cytek Biosciences, Inc. presented a mixed sentiment, reflecting ...

“Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position,” said Wenbin Jiang, CEO of Cytek Biosciences. “As we ...